---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-005190"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T07:57:53.564200+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Insmed reports Q4 ARIKAYCE revenue $104.4M; brensocatib NDA accepted with Priority Review

## Summary
- Full-year 2024 ARIKAYCE revenue $363.7M (+19% YoY); Q4 net loss $235.5M ($1.32/share).
- Brensocatib NDA for bronchiectasis accepted by FDA with Priority Review; PDUFA date Aug 12, 2025.
- Company reiterates FY2025 ARIKAYCE revenue guidance $405M–$425M (11-17% YoY growth).
- Cash, equivalents, and marketable securities approx. $1.4B as of Dec 31, 2024.
- Director Alfred Altomari will not stand for re-election at 2025 Annual Meeting; no disagreement.

## SEC filing metadata
- accession: 0001140361-25-005190
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/0001140361-25-005190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-005190
- JSON: https://secwatch.observer/filing/0001140361-25-005190.json
- Plain text: https://secwatch.observer/filing/0001140361-25-005190.txt

## Key facts
- Executive change
  Alfred Altomari departed as Director at INSMED Inc.
  - Action: will not stand for re-election
  - Role: Director
  source text: On February 18, 2025, Alfred Altomari notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/0001140361-25-005190-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.